Dimensional Fund Advisors
ACAD icon

Dimensional Fund Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Dimensional Fund Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.2M Buy
3,155,160
+234,186
+8% +$5.6M 0.01% 1311
2025
Q4 		$78M Buy
2,920,974
+122,840
+4% +$2.94M 0.02% 1245
2025
Q3 		$59.7M Buy
2,798,134
+402,534
+17% +$9.52M 0.01% 1414
2025
Q2 		$51.7M Buy
2,395,600
+740,230
+45% +$13.8M 0.01% 1479
2025
Q1 		$27.5M Buy
1,655,370
+568,530
+52% +$10.3M 0.01% 1796
2024
Q4 		$19.9M Buy
1,086,840
+243,082
+29% +$3.92M ﹤0.01% 1999
2024
Q3 		$13M Buy
843,758
+194,608
+30% +$3.25M ﹤0.01% 2194
2024
Q2 		$10.5M Buy
+649,150
New +$10.5M ﹤0.01% 2241
2024
Q1 		– Sell
-36,754
Closed -$1.15M – 3388
2023
Q4 		$1.15M Sell
36,754
-56,583
-61% -$1.35M ﹤0.01% 2904
2023
Q3 		$1.95M Sell
93,337
-9,004
-9% -$245K ﹤0.01% 2789
2023
Q2 		$2.45M Sell
102,341
-27,900
-21% -$620K ﹤0.01% 2722
2023
Q1 		$2.45M Sell
130,241
-186,223
-59% -$3.55M ﹤0.01% 2693
2022
Q4 		$5.04K Sell
316,464
-39,951
-11% -$624K ﹤0.01% 2455
2022
Q3 		$5.83M Sell
356,415
-136,513
-28% -$2.21M ﹤0.01% 2375
2022
Q2 		$6.95M Sell
492,928
-148,295
-23% -$2.77M ﹤0.01% 2346
2022
Q1 		$15.5M Sell
641,223
-19,029
-3% -$460K ﹤0.01% 2104
2021
Q4 		$15.4M Buy
660,252
+368,365
+126% +$7.41M ﹤0.01% 2128
2021
Q3 		$4.85M Sell
291,887
-14,109
-5% -$272K ﹤0.01% 2595
2021
Q2 		$7.46M Sell
305,996
-46,821
-13% -$1.06M ﹤0.01% 2473
2021
Q1 		$9.1M Buy
352,817
+15,670
+5% +$690K ﹤0.01% 2364
2020
Q4 		$18M Buy
337,147
+9,930
+3% +$493K 0.01% 2032
2020
Q3 		$13.5M Buy
327,217
+15,310
+5% +$661K 0.01% 2054
2020
Q2 		$15.1M Buy
311,907
+20,503
+7% +$984K 0.01% 2014
2020
Q1 		$12.3M Sell
291,404
-4,820
-2% -$199K 0.01% 2013
2019
Q4 		$12.7M Buy
296,224
+172,921
+140% +$7.52M ﹤0.01% 2262
2019
Q3 		$4.44M Buy
+123,303
New +$3.74M ﹤0.01% 2641
2018
Q1 		– Sell
-11,543
Closed -$348K – 3346
2017
Q4 		$348K Sell
11,543
-76,252
-87% -$2.44M ﹤0.01% 3146
2017
Q3 		$3.31M Buy
+87,795
New +$2.86M ﹤0.01% 2724
2017
Q2 		– Sell
-198,620
Closed -$6.83M – 3312
2017
Q1 		$6.83M Buy
198,620
+190,981
+2,500% +$6.74M ﹤0.01% 2464
2016
Q4 		$220K Sell
7,639
-217,765
-97% -$5.76M ﹤0.01% 3190
2016
Q3 		$7.17M Buy
225,404
+91,978
+69% +$3.12M ﹤0.01% 2380
2016
Q2 		$4.33M Buy
+133,426
New +$4.47M ﹤0.01% 2551
2016
Q1 		– Sell
-150,666
Closed -$5.37M – 3300
2015
Q4 		$5.37M Buy
150,666
+1,739
+1% +$61.3K ﹤0.01% 2487
2015
Q3 		$4.92M Buy
148,927
+6,797
+5% +$283K ﹤0.01% 2526
2015
Q2 		$5.95M Buy
142,130
+27,365
+24% +$1.06M ﹤0.01% 2511
2015
Q1 		$3.74M Buy
114,765
+57,224
+99% +$1.97M ﹤0.01% 2648
2014
Q4 		$1.83M Buy
+57,541
New +$1.63M ﹤0.01% 2861
2014
Q1 		– Sell
-177,433
Closed -$4.43M – 3595
2013
Q4 		$4.43M Buy
+177,433
New +$4.19M ﹤0.01% 2609

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors's ACAD Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 8% in Q1 2026, buying an estimated $5.6M and bringing the position to 3,155,160 shares worth $70.2M. The position accounts for 0.01% of the portfolio, ranked #1311.

Dimensional Fund Advisors first reported a position in ACAD in Q4 2013 and has held it in 38 quarters since. The position peaked at $78M in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Dimensional Fund Advisors held 3,155,160 shares of Acadia Pharmaceuticals worth $70.2M as of Q1 2026.
  • Dimensional Fund Advisors bought 234,186 Acadia Pharmaceuticals shares in Q1 2026, an estimated $5.6M.
  • Acadia Pharmaceuticals made up 0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #1311 holding.
  • Dimensional Fund Advisors first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 38 quarters since.
  • Dimensional Fund Advisors's Acadia Pharmaceuticals position peaked at $78M in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.